Celyad Oncology Announces September 2021 Conferences Schedule
01 sept. 2021 01h00 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights
04 août 2021 16h01 HE
|
Celyad Oncology SA
•Enrollment continues at dose level three in Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in relapsed/refractory multiple myeloma (r/r MM); next clinical update expected by year-end 2021 •Phase 1b...
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
30 juil. 2021 01h00 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, July 30, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology to Announce First Half 2021 Financial Results and Host Conference Call
29 juil. 2021 01h00 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, July 29, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Research & Development Day
20 juil. 2021 16h01 HE
|
Celyad Oncology SA
Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in relapsed/refractory multiple myeloma (r/r MM) showed dose dependent engraftment up to dose level three (300×106 cells per infusion) with no...
Celyad Oncology to Host Virtual Research & Development Webinar on July 20th
13 juil. 2021 16h01 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, July 13, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology to Participate at the William Blair Biotech Focus Conference 2021
07 juil. 2021 16h01 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, July 07, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
30 juin 2021 01h00 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, June 30, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress
11 juin 2021 02h59 HE
|
Celyad Oncology SA
Treatment with CYAD-211 generally well-tolerated at first two dose levels, with no evidence of Graft-versus-Host Disease observedTwo partial responses observed among five evaluable patientsCell...
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
31 mai 2021 01h00 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 31, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...